Curevac announces positive data in older adults from covid-19 and flu mrna vaccine development programs

Continued technology platform validation with extended preliminary data from older adults in ongoing phase 1 studies in covid-19 and flu covid-19: monovalent modified mrna construct cv0501 successfully boosted antibody titers against ba.1 and ancestral variants in adults age ≥65 flu: monovalent modified mrna construct flu-sv-mrna elicited antibodies approximately 2.3 times those of licensed vaccine comparator in adults aged 60-80 reaffirming plan to advance modified mrna covid-19 and flu candidates to the next stages of clinical development in collaboration with gsk in 2023 tÜbingen, germany and boston, ma / accesswire / january 30, 2023 / curevac n.v. (nasdaq:cvac), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced positive extended preliminary data from ongoing phase 1 clinical programs in covid-19 and seasonal flu conducted in collaboration with gsk.
CVAC Ratings Summary
CVAC Quant Ranking